Free Trial
NASDAQ:FBLG

FibroBiologics Q2 2024 Earnings Report

FibroBiologics logo
$0.90 +0.01 (+1.58%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$0.88 -0.02 (-2.32%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
7:30AM ET

Upcoming Earnings

FibroBiologics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 5:25 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

FibroBiologics Earnings Headlines

FibroBiologics Presenting at the ThymUS 2025 Meeting
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
FibroBiologics announces opening of new lab facility
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat